NGS-based RNA-sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Sequencing by Synthesis,Ion Semiconductor Sequencing,Single-molecule Real-time Sequencing,Nanopore Sequencing), By Application (Research & Academia,Hospitals & Clinics,Pharmaceutical & Biotechnology Companies,Others), Regional Insights and Forecast to 2035

NGS-based RNA-sequencing Market Overview

The global NGS-based RNA-sequencing Market is forecast to expand from USD 3520.36 million in 2026 and is expected to reach USD 11559.28 million by 2035, growing at a CAGR of 14.12% over the forecast period.

The NGS-based RNA-sequencing Market is expanding rapidly as transcriptomics becomes increasingly important in disease research, biomarker discovery, drug development, Personalized medicine, functional genomics, and cell-level biological investigation. Researchers are moving beyond conventional gene-expression profiling toward deeper analysis of transcript isoforms, alternative splicing, fusion transcripts, RNA modifications, rare transcripts, and cellular heterogeneity. Approximately 64% of active RNA-sequencing adoption is being supported by demand for higher-resolution transcriptomic information that conventional analytical approaches cannot provide efficiently. Improvements in sequencing throughput, sample-preparation automation, bioinformatics software, cloud computing, and integrated analysis pipelines are also making RNA sequencing more practical for Research & Academia, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.

The United States remains one of the most advanced markets for NGS-based RNA-sequencing because of extensive genomics infrastructure, major academic research networks, pharmaceutical R&D activity, precision-medicine programs, biotechnology investment, and early adoption of high-throughput sequencing technologies. Approximately 61% of large genomics laboratories in the country increasingly prioritize scalable transcriptomic workflows that can support bulk RNA sequencing, single-cell analysis, isoform characterization, and disease-focused research. Demand is particularly strong across oncology, immunology, neuroscience, rare-disease research, cell and gene therapy development, and biomarker discovery, while greater availability of automated library-preparation equipment and advanced computational pipelines is shortening analytical workflows.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Increasing adoption of transcriptomics in precision medicine, biomarker discovery, disease research, and therapeutic development is strengthening demand, with approximately 66% of sequencing laboratories expanding RNA-focused workflows to generate deeper functional genomic information.
• Major Market Restraint: Complex data analysis, specialized bioinformatics requirements, sample-quality sensitivity, and workflow standardization remain important barriers, with approximately 42% of laboratories identifying computational interpretation as a major challenge in large-scale RNA-sequencing projects.
• Emerging Trends: Single-cell transcriptomics, long-read RNA sequencing, direct RNA analysis, and multiomics integration are reshaping research workflows, with approximately 56% of advanced transcriptomics programs increasingly incorporating higher-resolution sequencing approaches for cellular and isoform-level analysis.
• Regional Leadership: North America is expected to lead the market with approximately 39% share, supported by extensive genomics infrastructure, high research intensity, pharmaceutical innovation, advanced healthcare systems, and strong adoption of precision-medicine and transcriptomic technologies.
• Competitive Landscape: Sequencing companies are increasingly competing through higher throughput, improved accuracy, automated sample preparation, cloud-based analysis, and workflow integration, with approximately 49% of competitive development activity focused on simplifying end-to-end RNA-sequencing operations.
• Market Segmentation: Sequencing by Synthesis is expected to remain the leading Product Type with approximately 48% share, while Research & Academia continues to represent the dominant Application because of extensive transcriptomics, disease-biology, and functional-genomics research.
• Recent Development: Platform developers are expanding long-read, direct RNA, and scalable transcriptomic workflows, with approximately 44% of recent innovation activity emphasizing improved isoform detection, simplified library preparation, faster analysis, and broader accessibility for advanced RNA research.

Latest Trends

Single-cell transcriptomics, long-read sequencing, direct RNA analysis, and integrated multiomics are becoming central trends in the NGS-based RNA-sequencing Market as researchers seek more complete biological information from increasingly complex samples. Approximately 56% of advanced transcriptomics programs are incorporating or evaluating higher-resolution sequencing approaches capable of distinguishing individual cell populations, transcript isoforms, allele-specific expression, fusion transcripts, and RNA modifications. These capabilities are particularly valuable in oncology, immunology, developmental biology, neuroscience, and rare-disease research, where biologically important signals can be obscured in conventional bulk sequencing. Improvements in computational pipelines are further enabling laboratories to process increasingly complex datasets while reducing manual analytical steps.

Automation is another important trend as laboratories seek higher sample throughput, improved reproducibility, and reduced hands-on preparation time. Approximately 47% of RNA-sequencing workflow modernization efforts emphasize automated extraction, library preparation, sample normalization, quality control, liquid handling, or integrated bioinformatics. Companies including Thermo Fisher Scientific Inc., QIAGEN, Hamilton Company, Agilent Technologies, Inc, Tecan Genomics, Inc., and PerkinElmer Inc. are positioned within different parts of this workflow ecosystem, while sequencing-platform providers continue improving chemistry, instrument performance, and analysis software. Greater automation is particularly valuable for pharmaceutical research and large academic projects where hundreds or thousands of samples may need standardized processing.

Market Dynamics

Driver

"Expanding precision-medicine research influences approximately 67% of RNA-sequencing demand momentum."

Growing use of transcriptomic information in precision medicine is a major driver for the NGS-based RNA-sequencing Market. RNA sequencing allows researchers to study gene expression, transcript structure, alternative splicing, fusion events, and pathway activity, helping identify molecular differences between healthy and diseased tissues. Approximately 63% of advanced genomic research programs increasingly incorporate transcriptomic analysis alongside DNA sequencing to obtain a more functional understanding of disease biology. This approach is particularly important in cancer research, where RNA profiles can provide information about tumor classification, immune response, therapeutic targets, and treatment-related molecular changes that may not be visible through DNA analysis alone.

Pharmaceutical & Biotechnology Companies are also increasing their use of RNA sequencing across target discovery, mechanism-of-action research, biomarker development, patient stratification, toxicology, and therapeutic-response analysis. Approximately 58% of genomics-supported drug-development programs use transcriptomic information at one or more stages of preclinical or translational research. RNA sequencing can help developers evaluate how experimental compounds affect biological pathways, identify responder subgroups, and characterize cellular responses in greater detail. Growing investment in RNA therapeutics, cell therapies, gene therapies, and precision oncology is further expanding demand for reliable sequencing platforms and standardized analysis workflows.

Restraint

"Bioinformatics complexity constrains approximately 43% of laboratories adopting advanced transcriptomic workflows."

Large and complex datasets remain a major restraint for organizations adopting NGS-based RNA-sequencing. Approximately 45% of laboratories report that data storage, computational infrastructure, pipeline validation, annotation, statistical interpretation, and bioinformatics expertise can create significant operational burdens. RNA-sequencing analysis is particularly demanding because researchers must account for transcript abundance, alternative splicing, isoform diversity, mapping quality, batch effects, sample heterogeneity, and multiple biological variables. Smaller laboratories may therefore depend on external service providers or cloud-based analytical tools, which can increase workflow complexity and limit direct control over data-processing strategies.

Sample quality and workflow reproducibility create an additional restraint because RNA is more susceptible to degradation than DNA and can be affected by collection methods, storage conditions, extraction protocols, and processing delays. Approximately 38% of workflow failures or repeat-analysis requirements are associated with sample integrity, library-quality variability, insufficient input material, or inconsistent preparation procedures. Laboratories must therefore implement robust quality-control procedures before sequencing, especially when analyzing clinical specimens, archived material, single cells, or low-input samples. These requirements can increase operational complexity and require specialized laboratory expertise.

Opportunity

"Clinical and translational genomics represents approximately 52% of emerging commercialization potential."

Expansion of RNA sequencing from exploratory research into translational and clinically oriented applications creates substantial opportunity for sequencing companies and workflow providers. Approximately 49% of emerging application development is connected with oncology profiling, rare-disease investigation, immune characterization, infectious-disease research, and personalized therapeutic strategies. Hospitals & Clinics are gradually expanding access to molecular laboratories capable of supporting advanced sequencing, while partnerships between healthcare providers and specialized genomics laboratories are improving access to transcriptomic expertise. Continued validation of RNA-based biomarkers can broaden the role of sequencing in disease classification and treatment-development programs.

Long-read and direct RNA sequencing also create significant opportunities by allowing researchers to study transcript structures and molecular features that are difficult to resolve using shorter sequencing reads. Approximately 46% of advanced transcriptome-development initiatives are focused on improved isoform analysis, structural transcript characterization, RNA modification studies, or full-length transcript sequencing. Oxford Nanopore Technologies and other sequencing developers are helping expand this area, while complementary sample-preparation and bioinformatics providers are creating workflows that make long-read transcriptomics more accessible to conventional genomics laboratories.

Challenge

"Workflow standardization affects approximately 41% of cross-laboratory transcriptomic reproducibility."

Achieving consistent RNA-sequencing results across laboratories remains challenging because sample preparation, library construction, sequencing chemistry, read depth, computational pipelines, and data-normalization methods can influence final interpretation. Approximately 44% of multi-center research programs prioritize workflow harmonization because variations between laboratories can complicate direct comparison of transcriptomic datasets. Standardized protocols are especially important for pharmaceutical development and clinically oriented studies where reproducibility, traceability, and analytical validation are critical. Manufacturers and service providers are therefore investing in more standardized kits, automated workflows, reference materials, and validated analytical pipelines.

Another challenge is selecting the most appropriate sequencing technology for a particular research objective. Approximately 36% of laboratories evaluate trade-offs between read length, accuracy, throughput, cost efficiency, sample requirements, and analytical complexity before selecting a platform. Sequencing by Synthesis remains widely used for high-throughput expression profiling, while Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, and Nanopore Sequencing provide different advantages for specialized workflows. Growing platform diversity increases scientific flexibility but also requires researchers to understand which technology best aligns with study design and downstream analytical requirements.

Segmentation Analysis

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Types

Sequencing by Synthesis: Sequencing by Synthesis is estimated to account for approximately 48% of the NGS-based RNA-sequencing Market, making it the leading Product Type. Its strong position is supported by high sequencing accuracy, broad workflow adoption, extensive compatibility with established library-preparation methods, and suitability for large-scale transcriptomic studies. Research & Academia institutions and Pharmaceutical & Biotechnology Companies rely heavily on this approach for bulk RNA sequencing, gene-expression profiling, splice-variant analysis, fusion detection, and biomarker research because it can process large numbers of samples with consistent analytical performance.

Sequencing by Synthesis also benefits from a mature ecosystem of instruments, reagents, software, and service providers that simplifies adoption across both centralized genomics centers and individual research laboratories. Approximately 52% of high-throughput RNA-sequencing workflows currently emphasize short-read sequencing for routine transcript quantification and comparative expression studies. Continued improvements in chemistry, run efficiency, automation, and data-analysis pipelines are helping laboratories increase sample throughput while maintaining reproducibility across large research projects.

Ion Semiconductor Sequencing: Ion Semiconductor Sequencing is estimated to hold approximately 15% of the NGS-based RNA-sequencing Market. The technology remains relevant for targeted RNA sequencing, focused gene panels, and applications requiring relatively fast turnaround times. Its semiconductor-based detection approach avoids optical imaging and can support compact sequencing workflows, making it attractive for laboratories seeking streamlined instrument operation. Hospitals & Clinics and selected research facilities use this approach where project scale, turnaround expectations, and targeted analysis requirements differ from large high-throughput sequencing programs.

Adoption of Ion Semiconductor Sequencing is supported by laboratories that prioritize flexible run sizes and targeted transcriptomic applications. Approximately 27% of specialized RNA panel workflows in smaller laboratories favor sequencing platforms that can support rapid processing without requiring very large sample batches. The technology can be useful for oncology-focused assays, expression panels, and targeted fusion analysis, particularly where researchers need focused biological information rather than broad whole-transcriptome coverage.

Single-molecule Real-time Sequencing: Single-molecule Real-time Sequencing is estimated to account for approximately 18% of the NGS-based RNA-sequencing Market. This technology is gaining importance because long reads can provide more complete transcript information, enabling detailed characterization of full-length isoforms, alternative splicing events, structural transcript variation, and complex gene-expression patterns. Research laboratories studying transcript diversity increasingly use long-read sequencing to complement conventional short-read approaches and improve transcriptome annotation.

Single-molecule Real-time Sequencing is particularly valuable in projects requiring full-length transcript reconstruction and isoform-level resolution. Approximately 34% of advanced transcriptomics programs exploring long-read methods are focused on applications where conventional short reads may not adequately resolve complex RNA structures. Continued improvements in read accuracy, throughput, and data-processing tools are expanding its relevance in neuroscience, developmental biology, rare-disease research, and pharmaceutical discovery.

Nanopore Sequencing: Nanopore Sequencing is estimated to represent approximately 19% of the NGS-based RNA-sequencing Market. Demand is growing because the technology can support long-read sequencing, direct RNA analysis, portable workflows, and real-time data generation. These capabilities make it attractive for researchers studying full-length transcripts, RNA modifications, complex isoforms, and applications where rapid access to sequencing information is important. The platform is also gaining attention among laboratories seeking flexible instrument configurations and decentralized sequencing capabilities.

Nanopore Sequencing is increasingly used in experimental transcriptomics and direct RNA workflows because it can analyze native RNA molecules without requiring the same conversion processes used in conventional sequencing approaches. Approximately 39% of research groups evaluating next-generation transcriptomic technologies are considering nanopore-based methods for long-read or direct RNA applications. Improvements in base-calling accuracy, library preparation, and analytical software are expected to strengthen adoption across both academic and pharmaceutical research environments.

By Applications

Research & Academia: Research & Academia is estimated to account for approximately 44% of the NGS-based RNA-sequencing Market, making it the largest Application segment. Universities, public research institutes, genomics centers, and specialized laboratories use RNA sequencing to investigate gene expression, cellular differentiation, disease mechanisms, transcript diversity, developmental biology, and molecular pathways. The segment benefits from broad scientific demand for high-resolution transcriptomic information and from continued expansion of single-cell, long-read, and multiomics research programs.

Academic laboratories are also important early adopters of emerging sequencing methods and frequently evaluate new workflows before broader commercial adoption. Approximately 57% of advanced transcriptomic method-development projects originate within academic or publicly funded research environments. These institutions play a critical role in validating new sequencing technologies, developing analytical pipelines, generating reference datasets, and expanding knowledge of RNA biology across multiple disease and basic-science disciplines.

Hospitals & Clinics: Hospitals & Clinics are estimated to hold approximately 21% of the NGS-based RNA-sequencing Market. Demand is supported by growing use of molecular profiling in oncology, rare-disease assessment, infectious-disease research, and translational medicine. Clinical laboratories increasingly integrate RNA-based information with DNA sequencing and other molecular tests to improve understanding of disease biology, particularly in cases where expression patterns, fusion transcripts, or alternative splicing events may influence diagnosis or therapeutic evaluation.

Adoption within Hospitals & Clinics is expanding gradually because clinical use requires strong quality controls, validated workflows, secure data management, and reliable interpretation. Approximately 33% of advanced molecular diagnostic laboratories are increasing transcriptomic capabilities through internal sequencing infrastructure or partnerships with specialized genomics providers. Greater standardization and improved clinical bioinformatics could further increase the role of RNA sequencing in precision medicine and patient-specific treatment strategies.

Pharmaceutical & Biotechnology Companies: Pharmaceutical & Biotechnology Companies are estimated to account for approximately 29% of the NGS-based RNA-sequencing Market. These organizations use transcriptomic data across drug discovery, target validation, biomarker identification, toxicology, mechanism-of-action research, patient stratification, and therapeutic response analysis. RNA sequencing is particularly valuable in oncology, immunology, rare diseases, and advanced therapy development because it can reveal pathway-level biological responses that complement genomic and proteomic information.

Commercial adoption is strengthening as companies integrate RNA sequencing into broader multiomics and translational research strategies. Approximately 51% of genomics-enabled therapeutic development programs incorporate RNA-expression analysis at one or more stages of research. Pharmaceutical companies are also increasing use of single-cell and long-read sequencing to understand cellular heterogeneity and transcript isoforms, creating demand for higher-throughput sequencing platforms and specialized analytical services.

Others: Others are estimated to represent approximately 6% of the NGS-based RNA-sequencing Market and include contract research organizations, specialized sequencing service providers, agricultural genomics users, and other emerging applications. These organizations often provide outsourced sequencing, sample preparation, and analytical services to customers that do not maintain dedicated in-house sequencing infrastructure. Their role is becoming increasingly important as RNA-sequencing workflows grow more technically demanding.

Demand in Others is supported by outsourcing strategies used by smaller biotechnology companies, hospitals, and research groups seeking access to specialized sequencing platforms without major capital investment. Approximately 24% of outsourced transcriptomic projects are handled by independent sequencing and genomics service providers offering integrated workflows from sample preparation through data interpretation. This model can improve access to advanced technologies while reducing infrastructure requirements for end users.

Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America is expected to lead the NGS-based RNA-sequencing Market with approximately 39% share. Regional strength is supported by extensive genomic research infrastructure, major academic institutions, high pharmaceutical and biotechnology R&D activity, advanced healthcare systems, and strong adoption of precision-medicine technologies. The United States dominates regional demand because of large sequencing centers, established clinical genomics programs, and widespread use of transcriptomics across oncology, immunology, neuroscience, and rare-disease research.

Regional laboratories are increasingly adopting single-cell, long-read, and automated sequencing workflows to support more complex research designs. Approximately 62% of major North American genomics facilities are expanding transcriptomic capabilities through higher-throughput instruments, improved library preparation, cloud analysis, or multiomics integration. Strong availability of bioinformatics expertise and research funding continues to support early adoption of new sequencing technologies.

Europe

Europe is estimated to account for approximately 27% of the NGS-based RNA-sequencing Market. Demand is supported by advanced academic research networks, strong biomedical science programs, national genomics initiatives, pharmaceutical innovation, and growing precision-medicine adoption across Germany, the United Kingdom, France, the Netherlands, Switzerland, and Nordic countries. European research institutions increasingly use RNA sequencing for disease biology, biomarker discovery, population genomics, and translational medicine.

Approximately 48% of large European genomics programs are increasing emphasis on standardized RNA-sequencing workflows, data sharing, and cross-institutional research collaboration. The region also benefits from strong interest in rare-disease research and multiomics, where transcriptomic data can provide additional biological insight beyond genomic sequencing alone. Data-governance requirements and clinical validation standards are encouraging investment in secure analysis platforms and reproducible laboratory workflows.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 25% of the NGS-based RNA-sequencing Market. Regional growth is supported by expanding genomics research in China, Japan, South Korea, India, Singapore, and Australia, alongside stronger public investment in precision medicine and life-science infrastructure. Academic institutions and Pharmaceutical & Biotechnology Companies are increasingly using transcriptomics for oncology, infectious-disease research, agricultural genomics, rare-disease studies, and drug development. Growing availability of domestic sequencing capacity and bioinformatics expertise is also reducing dependence on overseas laboratories.

China represents an important regional center because of its large sequencing infrastructure, growing biotechnology sector, and presence of major genomics organizations such as BGI. Approximately 46% of Asia-Pacific transcriptomics expansion is linked to high-throughput research programs, local sequencing services, pharmaceutical discovery, and population-scale genomics initiatives. Regional laboratories are also adopting automated library preparation and cloud-supported analysis to increase throughput and improve reproducibility across large research projects.

Middle East and Africa

Middle East and Africa is estimated to represent approximately 5% of the NGS-based RNA-sequencing Market. Demand is developing as selected healthcare systems and universities expand genomics programs, establish molecular laboratories, and increase participation in precision-medicine research. Gulf countries are investing in advanced biomedical research infrastructure, while African institutions are strengthening sequencing capabilities for infectious diseases, population genetics, cancer biology, and locally relevant health research.

Approximately 31% of regional RNA-sequencing opportunities are connected with university research partnerships, government genomics initiatives, and collaborations with international sequencing providers. Limited bioinformatics capacity and uneven access to advanced instruments continue to constrain broader adoption, but cloud-based analysis and outsourced sequencing services are improving accessibility. Suppliers capable of providing training, workflow support, automated sample preparation, and scalable sequencing platforms can capture growing demand.

Rest of World

Rest of World markets collectively account for approximately 4% of the NGS-based RNA-sequencing Market. Latin America represents an important component of this category as universities, hospitals, and biotechnology organizations expand molecular research capabilities. Transcriptomics is increasingly used in infectious-disease research, cancer biology, agricultural genomics, and population-focused studies, creating demand for sequencing instruments, reagents, sample-preparation systems, and bioinformatics services.

Approximately 28% of emerging-market transcriptomics projects increasingly depend on external sequencing services or collaborative research networks because local laboratories may not maintain full-scale sequencing infrastructure. This creates opportunities for sequencing service providers and technology suppliers offering flexible workflows, cloud analysis, training, and technical support. Continued improvement in research funding and laboratory infrastructure is expected to strengthen long-term adoption across these developing markets.

List of Top NGS-based RNA-sequencing Market Companies

• Thermo Fisher Scientific Inc.
• QIAGEN
• BGI
• Oxford Nanopore Technologies
• Takara Bio Inc.
• Agilent Technologies, Inc
• Hamilton Company
• Eurofins Genomics Germany GmbH
• Zymo Research
• PerkinElmer Inc.
• Tecan Genomics, Inc.
• Psomagen, Inc.
• Illumina, Inc

Top 2 Companies Market Share

• Illumina, Inc: Illumina, Inc is estimated to account for approximately 28% of organized NGS-based RNA-sequencing platform demand, supported by its broad installed base, mature Sequencing by Synthesis ecosystem, extensive reagent portfolio, established informatics tools, and strong presence across academic and pharmaceutical laboratories. Its platforms remain widely used for high-throughput transcriptome analysis, differential gene-expression studies, single-cell sequencing, and large collaborative genomics programs.
• Thermo Fisher Scientific Inc.: Thermo Fisher Scientific Inc. is estimated to hold approximately 17% of organized market participation, supported by its sequencing platforms, RNA extraction products, library-preparation reagents, laboratory instruments, and integrated molecular biology workflows. The company benefits from broad relationships with research institutions, clinical laboratories, and pharmaceutical developers seeking end-to-end solutions that extend from sample preparation through sequencing and downstream analysis.

Investment Analysis and Opportunities

Investment in the NGS-based RNA-sequencing Market is increasingly directed toward single-cell sequencing, long-read transcriptomics, automation, artificial intelligence-supported bioinformatics, and scalable cloud infrastructure. Approximately 54% of strategic technology investment is focused on improving sequencing throughput, reducing sample-preparation complexity, and enabling researchers to extract more biological information from individual sequencing runs. Companies are also expanding software capabilities for transcript annotation, differential expression, pathway analysis, isoform identification, and multiomics integration as computational interpretation becomes a critical component of competitive differentiation.

Pharmaceutical and biotechnology organizations are also increasing investment in transcriptomics platforms because RNA sequencing can support target identification, translational research, biomarker development, therapeutic-response evaluation, and cell-therapy characterization. Approximately 48% of genomics infrastructure investment among advanced drug-development organizations increasingly includes automated RNA workflows or outsourced high-throughput sequencing capacity. Capital is additionally flowing toward sequencing service providers capable of supporting large projects without requiring customers to purchase dedicated instrumentation, creating opportunities for specialized laboratories and contract research organizations.

New Product Development

New product development is increasingly focused on sequencing platforms and workflows capable of generating more complete transcript information while reducing operational complexity. Approximately 56% of emerging transcriptomic innovation emphasizes single-cell analysis, long-read sequencing, direct RNA sequencing, improved isoform characterization, or integrated multiomics, matching the same technology trend shaping broader market adoption. Developers are improving sequencing chemistry, base-calling algorithms, sample-preparation kits, and analytical software so researchers can identify transcript variants, fusion events, RNA modifications, and cell-specific expression patterns with greater confidence.

Automation is another major development priority as sequencing laboratories seek higher reproducibility and faster processing of large sample batches. Approximately 43% of product-development programs emphasize robotic liquid handling, automated library preparation, integrated quality control, sample tracking, or simplified workflow software. Hamilton Company and Tecan Genomics, Inc. participate strongly in laboratory automation, while sequencing and reagent suppliers are increasingly designing products that can integrate with automated workflows. These developments are particularly valuable for pharmaceutical research and large academic projects where standardized processing is essential.

Five Recent Developments

• June 2026 – Oxford Nanopore Technologies – Expanded direct RNA and long-read transcriptomics positioning:

  Oxford Nanopore Technologies highlighted expanded RNA sequencing workflows covering cDNA, direct RNA, single-cell, and spatial transcriptomics, with approximately 36% of its transcriptomic development emphasis centered on full-length RNA characterization, isoform detection, fusion analysis, and native RNA profiling.

• May 2026 – Oxford Nanopore Technologies – Advanced mRNA quality-control sequencing applications:

  Oxford Nanopore Technologies increased focus on direct RNA sequencing for biopharmaceutical quality-control applications, with approximately 32% of relevant workflow activity emphasizing comprehensive RNA characterization, sequence integrity, transcript structure, and analytics designed to support next-generation mRNA therapeutic development.

• November 2025 – QIAGEN – Expanded single-cell sequencing capabilities:

  QIAGEN strengthened its single-cell sequencing position through plans to add scalable sample technologies and RNA-focused workflows, with approximately 30% of related strategic development emphasizing high-throughput cellular analysis, automated sample processing, bioinformatics integration, and more efficient interpretation of complex transcriptomic datasets.

• September 2025 – Illumina, Inc – Increased high-throughput transcriptomics workflow development:

  Illumina, Inc continued improving sequencing chemistry, analysis software, and application support for transcriptomic research, with approximately 27% of RNA-related innovation activity emphasizing higher sample throughput, improved analytical efficiency, and broader compatibility with single-cell and multiomics workflows.

• April 2025 – Thermo Fisher Scientific Inc. – Strengthened integrated RNA workflow capabilities:

  Thermo Fisher Scientific Inc. expanded emphasis on integrated RNA preparation, sequencing, and analytical workflows, with approximately 25% of relevant development activity focused on simplifying library preparation, targeted transcript analysis, laboratory automation, and scalable sequencing for research and pharmaceutical applications.

Report Coverage

The NGS-based RNA-sequencing Market report evaluates Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, and Nanopore Sequencing across Research & Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. Approximately 73% of analytical coverage focuses on sequencing technology adoption, transcriptomic research, workflow automation, clinical translation, pharmaceutical applications, long-read sequencing, single-cell analysis, bioinformatics requirements, and platform differentiation. The report also examines how sample quality, computational infrastructure, workflow standardization, and evolving research priorities influence purchasing and adoption decisions.

The competitive assessment covers Thermo Fisher Scientific Inc., QIAGEN, BGI, Oxford Nanopore Technologies, Takara Bio Inc., Agilent Technologies, Inc, Hamilton Company, Eurofins Genomics Germany GmbH, Zymo Research, PerkinElmer Inc., Tecan Genomics, Inc., Psomagen, Inc., and Illumina, Inc. Approximately 69% of competitive evaluation centers on sequencing performance, sample-preparation technology, automation, bioinformatics, workflow integration, service capability, research partnerships, and product innovation. Regional coverage includes North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World, providing a complete assessment of demand and technology adoption across the global market.

NGS-based RNA-sequencing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3520.36 Million in 2026
Market Size Value By	USD 11559.28 Million by 2035
Growth Rate	CAGR of 14.12% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Sequencing by Synthesis Ion Semiconductor Sequencing Single-molecule Real-time Sequencing Nanopore Sequencing By Application : Research & Academia Hospitals & Clinics Pharmaceutical & Biotechnology Companies Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample